Treating acne with antibiotic-resistant bacterial colonization

Bibliography

• Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol 2004;22:360-6
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Eady A, Philpott M, What is the pathogenesis of acne? Exp Dermatol 2005;14:143-52
   PubMed Web of Science ®Google Scholar
• Kurokawa I, Danby FW, Ju Q, New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009;18:821-32
   PubMed Web of Science ®Google Scholar
• Picardo M, Ottaviani M, Camera E, Mastrofrancesco A. Sebaceous gland lipids. Dermatoendocrinol 2009;1:68-71
   PubMedGoogle Scholar
• Zouboulis CC. The human skin as a hormone target and an endocrine gland. Hormones 2004;3:9-26
   PubMedGoogle Scholar
• Zouboulis CC. The skin as an endocrine organ. Dermatoendocrinol 2009;1:250-2
   PubMedGoogle Scholar
• Zouboulis CC. Is acne vulgaris a genuine inflammatory disease? Dermatology 2001;203:277-9
   PubMed Web of Science ®Google Scholar
• Ghodsi SZ, Orawa H, Zouboulis CC. Prevalence, severity and severity risk factors of acne in high school pupils: a community-based study. J Invest Dermatol 2009;129:2136-41
   PubMed Web of Science ®Google Scholar
• Dessinioti C, Katsambas AD. The role of propionibacterium acnes in acne pathogenesis: facts and controversies. Clin Dermatol 2010;28:2-7
   PubMed Web of Science ®Google Scholar
• Tan AW, Tan HH. Acne vulgaris: a review of antibiotic therapy. Expert Opin Pharmacother 2005;6:409-18
   PubMed Web of Science ®Google Scholar
• Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003;206:54-6
   PubMed Web of Science ®Google Scholar
• Kamisango K, Saiki I, Tanio Y, Structures and biological activities of peptidoglycans of Listeria monocytogenes and propionibacterium acnes. J Biochem 1982;92:23-33
   PubMedGoogle Scholar
• Sugisaki H, Yamanaka K, Kakeda M, Increased interferon-gamma, interleukin-12p40 and IL-8 production in propionibacterium acnes-treated peripheral blood mononuclear cells from patient with acne vulgaris: host response but not bacterial species is the determinant factor of the disease. J Dermatol Sci 2009;55:47-52
   PubMed Web of Science ®Google Scholar
• Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun 1995;63:3158-65
   PubMed Web of Science ®Google Scholar
• Kim J, Ochoa MT, Krutzik SR, Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002;169:1535-41
   PubMed Web of Science ®Google Scholar
• Kim J. Review of the innate immune response in acne vulgaris: activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology 2005;211:193-8
   PubMed Web of Science ®Google Scholar
• Jeremy AH, Holland DB, Roberts SG, Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003;121:20-7
   PubMed Web of Science ®Google Scholar
• Krause K, Schnitger A, Fimmel S, Corticotropin-releasing hormone skin signaling is receptor-mediated and is predominant in the sebaceous glands. Horm Metab Res 2007;39:166-70
   PubMed Web of Science ®Google Scholar
• Isard O, Knol AC, Castex-Rizzi N, Cutaneous induction of corticotropin releasing hormone by propionibacterium acnes extracts. Dermatoendocrinol 2009;1:96-9
   PubMedGoogle Scholar
• Zouboulis CC. Propionibacterium acnes and sebaceous lipogenesis: a love-hate relationship? J Invest Dermatol 2009;129:2093-6
   Google Scholar
• Bruggemann H, Henne A, Hoster F, The complete genome sequence of propionibacterium acnes, a commensal of human skin. Science 2004;305:671-3
   PubMed Web of Science ®Google Scholar
• Nakatsuji T, Liu YT, Huang CP, Vaccination targeting a surface sialidase of P. acnes: implication for new treatment of acne vulgaris. PLoS ONE 2008;3:e1551
   PubMed Web of Science ®Google Scholar
• Koreck A, Pivarcsi A, Dobozy A, Kemeny L. The role of innate immunity in the pathogenesis of acne. Dermatology 2003;206:96-105
   PubMed Web of Science ®Google Scholar
• Georgel P, Crozat K, Lauth X, A toll-like receptor 2-responsive lipid effector pathway protects mammals against skin infections with gram-positive bacteria. Infect Immun 2005;73:4512-21
   PubMed Web of Science ®Google Scholar
• Nagy I, Pivarcsi A, Kis K, Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect 2006;8:2195-205
   PubMed Web of Science ®Google Scholar
• Nagy I, Pivarcsi A, Koreck A, Distinct strains of Propionibacterium acnes induce selective human beta-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J Invest Dermatol 2005;124:931-8
   PubMed Web of Science ®Google Scholar
• Leyden JJ, McGinley KJ, Cavalieri S, Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983;8:41-5
   PubMed Web of Science ®Google Scholar
• Ross JI, Snelling AM, Carnegie E, Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003;148:467-78
   PubMed Web of Science ®Google Scholar
• Eady EA. Bacterial resistance in acne. Dermatology 1998;196:59-66
   PubMed Web of Science ®Google Scholar
• Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant?: implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003;4:813-31
   PubMed Web of Science ®Google Scholar
• Nord CE, Oprica C. Antibiotic resistance in propionibacterium acnes. Microbiological and clinical aspects. Anaerobe 2006;12:207-10
   PubMed Web of Science ®Google Scholar
• Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002;34:482-92
   PubMed Web of Science ®Google Scholar
• Ross JI, Eady EA, Carnegie E, Cove JH. Detection of transposon Tn5432-mediated macrolide-lincosamide-streptogramin B (MLSB) resistance in cutaneous propionibacteria from six European cities. J Antimicrob Chemother 2002;49:165-8
   Google Scholar
• Ross JI, Eady EA, Cove JH, Cunliffe WJ. 16S rRNA mutation associated with tetracycline resistance in a Gram-positive bacterium. Antimicrob Agents Chemother 1998;42:1702-5
   PubMed Web of Science ®Google Scholar
• Bernard P, Jarlier V, Santerre-Henriksen A. Antibiotic susceptibility of Staphylococcus aureus strains responsible for community-acquired skin infections. Ann Dermatol Venereol 2008;135:13-9
   PubMed Web of Science ®Google Scholar
• Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989;121:51-7
   PubMed Web of Science ®Google Scholar
• Ozolins M, Eady EA, Avery AJ, Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 2004;364:2188-95
   PubMed Web of Science ®Google Scholar
• Mills Jr O, Thornsberry C, Cardin CW, Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002;82:260-5
   Google Scholar
• Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005;153:395-403
   PubMed Web of Science ®Google Scholar
• Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15:167-93
   PubMed Web of Science ®Google Scholar
• Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358:135-8
   PubMed Web of Science ®Google Scholar
• Ramage G, Tunney MM, Patrick S, Formation of propionibacterium acnes biofilms on orthopaedic biomaterials and their susceptibility to antimicrobials. Biomaterials 2003;24:3221-7
   PubMed Web of Science ®Google Scholar
• Burkhart CN, Burkhart CG. Microbiology's principle of biofilms as a major factor in the pathogenesis of acne vulgaris. Int J Dermatol 2003;42:925-7
   PubMed Web of Science ®Google Scholar
• Coenye T, Peeters E, Nelis HJ. Biofilm formation by Propionibacterium acnes is associated with increased resistance to antimicrobial agents and increased production of putative virulence factors. Res Microbiol 2007;158:386-92
   PubMed Web of Science ®Google Scholar
• Degitz K, Ochsendorf F. Pharmacotherapy of acne. Expert Opin Pharmacother 2008;9:955-71
   PubMed Web of Science ®Google Scholar
• Leyden JJ. Antibiotic resistance in the topical treatment of acne vulgaris. Cutis 2004;73:6-10
   Google Scholar
• Guay DR. Topical clindamycin in the management of acne vulgaris. Expert Opin Pharmacother 2007;8:2625-64
   PubMed Web of Science ®Google Scholar
• Pickert A, Raimer S. An evaluation of dapsone gel 5% in the treatment of acne vulgaris. Expert Opin Pharmacother 2009;10:1515-21
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Appelbaum PC. Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opin Pharmacother 2006;7:1957-66
   PubMed Web of Science ®Google Scholar
• Garner SE, Eady EA, Popescu C, Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2003;(1):CD002086
   Google Scholar
• Grosshans E, Belaich S, Meynadier J, A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Eur J Dermatol 1998;8:161-6
   PubMed Web of Science ®Google Scholar
• Duran JM, Amsden GW. Azithromycin: indications for the future? Expert Opin Pharmacother 2000;1:489-505
   PubMedGoogle Scholar
• Weinberg JM. The anti-inflammatory effects of tetracyclines. Cutis 2005;75:6-11
   PubMed Web of Science ®Google Scholar
• Jain A, Sangal L, Basal E, Anti-inflammatory effects of erythromycin and tetracycline on propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 2002;8:2
   PubMedGoogle Scholar
• Griffin MO, Fricovsky E, Ceballos G, Villarreal FJ. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010;299:539-48
   PubMed Web of Science ®Google Scholar
• Toossi P, Farshchian M, Malekzad F, Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol 2008;7:1149-52
   PubMedGoogle Scholar
• Skidmore R, Kovach R, Walker C, Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003;39:459-64
   Google Scholar
• Simonart T. Antibiotic-resistant acne: lessons from good sense. Br J Dermatol 2004;150:369-70
   PubMed Web of Science ®Google Scholar
• Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother 2009;10:2555-62
   PubMed Web of Science ®Google Scholar
• Melnik BC, Schmitz G, Zouboulis CC. Anti-Acne agents attenuate FGFR2 signal transduction in acne. J Invest Dermatol 2009;129:1868-77
   PubMed Web of Science ®Google Scholar
• Gloor M, Klump H, Wirth H. Cytokinetic studies on the sebosuppressive effect of drugs using the example of benzoyl peroxide. Arch Dermatol Res 1980;167:97-9
   Google Scholar
• Burkhart CG, Butcher C, Burkhart CN, Lehmann P. Effects of benzoyl peroxide on lipogenesis in sebaceous glands using an animal model. J Cutan Med Surg 2000;4:138-41
   Google Scholar
• Taylor GA, Shalita AR. Benzoyl peroxide-based combination therapies for acne vulgaris: a comparative review. Am J Clin Dermatol 2004;5:261-5
   PubMed Web of Science ®Google Scholar
• Seidler EM, Kimball AB. Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. J Am Acad Dermatol 2010;63:52-62
   PubMed Web of Science ®Google Scholar
• Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002;24:1117-33
   PubMed Web of Science ®Google Scholar
• Ozolins M, Eady EA, Avery A, Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Health Technol Assess 2005;9:iii-212
   PubMed Web of Science ®Google Scholar
• Tan JKL. Adapalene 0.1% and benzoyl peroxide 2.5%: a novel combination for treatment of acne vulgaris. Skin Therapy Lett 2009;14:4-5
   PubMedGoogle Scholar
• Fleischer AB Jr, Shalita A, Eichenfield LF, Dapsone gel in combination treatment study group. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. J Drugs Dermatol 2010;9:33-40
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin 2009;27:33-42
   PubMed Web of Science ®Google Scholar
• Leyden JJ. Efficacy of benzoyl peroxide (5.3%) emollient foam and benzoyl peroxide (8%) wash in reducing propionibacterium acnes on the back. J Drugs Dermatol 2010;9:622-5
   PubMed Web of Science ®Google Scholar
• Leyden JJ, Wortzman M, Baldwin EK. Antibiotic-resistant propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. Cutis 2008;82:417-21
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Fischer TC, Wohlrab J, Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris. Cutis 2009;84:223-9
   PubMed Web of Science ®Google Scholar
• Braha S, Gafitanu E, Alexandrescu G, Antimicrobial activities of organic zinc compounds. Rev Med Chir Soc Med Nat Iasi 1992;96:249-52
   Google Scholar
• Bojar RA, Eady EA, Jones CE, Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994;130:329-36
   PubMed Web of Science ®Google Scholar
• Holland KT, Bojar RA, Cunliffe WJ, The effect of zinc and erythromycin on the growth of erythromycin-resistant and erythromycin sensitive isolates of propionibacterium acnes: an in-vitro study. Br J Dermatol 1992;126:505-9
   PubMedGoogle Scholar
• Dreno B, Foulc P, Reynaud A, Effect of zinc gluconate on propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study. Eur J Dermatol 2005;15:152-5
   PubMed Web of Science ®Google Scholar
• Van Hoogdalem EJ, Terpstra IJ, Baven AL. Evaluation of the effect of zinc acetate on the stratum corneum penetration kinetics of erythromycin in healthy male volunteers. Skin Pharmacol 1996;9:104-10
   PubMedGoogle Scholar
• Feucht CL, Allen BS, Chalker DK, Smith Jr JG. Topical erythromycin with zinc in acne. A double-blind controlled study. J Am Acad Dermatol 1980;3:483-91
   PubMed Web of Science ®Google Scholar
• Strauss JS, Stranieri AM. Acne treatment with topical erythromycin and zinc: effect of Propionibacterium acnes and free fatty acid composition. J Am Acad Dermatol 1984;11:86-9
   PubMed Web of Science ®Google Scholar
• Dreno B, Moyse D, Alirezai M, Acne Research and Study Group. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology 2001;203:135-40
   PubMed Web of Science ®Google Scholar
• Igic PG, Lee E, Harper W, Roach KW. Toxic effects associated with consumption of zinc. Mayo Clin Proc 2002;77:713-16
   PubMed Web of Science ®Google Scholar
• Oh CW, Myung KB. An ultrastructural study of the retention hyperkeratosis of experimentally induced comedones in rabbits: the effect of three comedolytics. J Dermatol 1996;23:169-80
   PubMedGoogle Scholar
• Melnik BC, Schmitz G, Zouboulis CC. Anti-acne agents attenuate FGFR2 signal transduction in acne. J Invest Dermatol 2009;129:1868-77
   PubMed Web of Science ®Google Scholar
• Akamatsu H, Komura J, Asada Y, Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res 1991;283:162-6
   PubMed Web of Science ®Google Scholar
• Webster G. Combination azelaic acid therapy for acne vulgaris. J Am Acad Dermatol 2000;43:47-50
   PubMed Web of Science ®Google Scholar
• Graupe K, Cunliffe WJ, Gollnick HP, Zaumseil RP. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis 1996;57:20-35
   PubMedGoogle Scholar
• Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001;11:538-44
   PubMed Web of Science ®Google Scholar
• Pazoki-Toroudi H, Nassiri-Kashani M, Tabatabaie H, Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. J Dermatol Treat 2010;21:212-16
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003;206:37-53
   Google Scholar
• Tsukada M, Schroder M, Roos TC, 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol 2000;115:321-7
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Korge B, Akamatsu H, Effects of 13-cis-retinoic acid, all-trans-retinoic acid, and acitretin on the proliferation, lipid synthesis and keratin expression of cultured human sebocytes in vitro. J Invest Dermatol 1991;96:792-7
   PubMed Web of Science ®Google Scholar
• Coates P, Vyakrnam S, Ravenscroft JC, Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne. Br J Dermatol 2005;153:1126-36
   PubMed Web of Science ®Google Scholar
• Oprica C, Emtestam L, Hagstromer L, Nord CE. Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris. Acta Derm Venereol 2007;87:246-54
   PubMed Web of Science ®Google Scholar
• Bowman S, Gold M, Nasir A, Vamvakias G. Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. J Drugs Dermatol 2005;4:611-18
   PubMedGoogle Scholar
• Jackson JM, Fu JJ, Almekinder JL. A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/ clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. J Drugs Dermatol 2010;9:131-6
   PubMed Web of Science ®Google Scholar
• Abdel-Naser MB, Zouboulis CC. Clindamycin phosphate/tretinoin gel formulation in the treatment of acne vulgaris. Expert Opin Pharmacother 2008;9:2931-7
   PubMed Web of Science ®Google Scholar
• Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatment for acne vulgaris. Expert Rev Dermatol 2007;2:693-706
   Google Scholar
• Zouboulis CC. The truth behind this undeniable efficacy – Recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology 2006;212:99-100
   PubMed Web of Science ®Google Scholar
• Nagl M, Hess MW, Pfaller K, Bactericidal activity of micromolar N-chlorotaurine: evidence for its antimicrobial function in the human defense system. Antimicrob Agents Chemother 2000;44:2507-13
   Google Scholar
• Marcinkiewicz J, Mak M, Bobek M, Is there a role of taurine bromamine in inflammation? Interactive effects with nitrate and hydrogen peroxide. Inflamm Res 2005;54:42-9
   Google Scholar
• Marcinkiewicz J, Biedron R, Białecka A, Susceptibility of Propionibacterium acnes and Staphylococcus epidermidis to killing by MPO-halide system products. Implication for taurine bromamine as a new candidate for topical therapy in treating acne vulgaris. Arch Immunol Ther Exp (Warsz) 2006;54:61-8
   Web of Science ®Google Scholar
• Marcinkiewicz J, Wojas-Pelc A, Walczewska M, Topical taurine bromamine, a new candidate in the treatment of moderate inflammatory acne vulgaris: a pilot study. Eur J Dermatol 2008;18:433-9
   PubMed Web of Science ®Google Scholar
• Melo MN, Dugourd D, Castanho MA. Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides. Recent Pat Antiinfect Drug Discov 2006;1:201-7
   PubMedGoogle Scholar
• Rubinchik E, Dugourd D, Algara T, Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Agents 2009;34:457-61
   PubMed Web of Science ®Google Scholar
• Marta Guarna M, Coulson R, Rubinchik E. Anti-inflammatory activity of cationic peptides: application to the treatment of acne vulgaris. FEMS Microbiol Lett 2006;257:1-6
   PubMed Web of Science ®Google Scholar
• Pan CY, Chen JY, Lin TL, Lin CH. In vitro activities of three synthetic peptides derived from epinecidin-1 and an anti-lipopolysaccharide factor against Propionibacterium acnes, Candida albicans, and Trichomonas vaginalis. Peptides 2009;30:1058-68
   PubMed Web of Science ®Google Scholar
• Shalita AR, Smith JG, Parish LC, Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol 1995;34:434-7
   PubMed Web of Science ®Google Scholar
• Draelos ZD, Matsubara A, Smiles K. The effect of 2% niacinamide on facial sebum production. J Cosmet Laser Ther 2006;8:96-101
   PubMedGoogle Scholar
• Sardesai VR, Kambli VM. Comparison of efficacy of topical clindamycin and nicotinamide combination with plain clindamycin for the treatment of acne vulgaris and acne resistant to topical antibiotics. Indian J Dermatol Venereol Leprol 2003;69:138-9
   Google Scholar
• Dos SK, Barbhuiya JN, Jana S, Dey SK. Comparative evaluation of clindamycin phosphate 1% and clindamycin phosphate 1% with nicotinamide gel 4% in the treatment of acne vulgaris. Indian J Dermatol Venereol Leprol 2003;69:8-9
   Google Scholar
• Grange PA, Raingeaud J, Calvez V, Dupin N. Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kappaB and MAPK pathways. J Dermatol Sci 2009;56:106-12
   PubMed Web of Science ®Google Scholar
• Thielitz A, Reinhold D, Vetter R, Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. J Invest Dermatol 2007;127:1042-51
   PubMed Web of Science ®Google Scholar
• Alestas T, Ganceviciene R, Fimmel S, Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med 2006;84:75-87
   PubMed Web of Science ®Google Scholar
• Devchand PR, Keller H, Peters JM, The PPAR-alpha leukotriene-B4 pathway to inflammation control. Nature 1996;384:39-43
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Leukotrien-antagonisten bei atopischen Erkrankungen und Akne. Akt Dermatol 2003;29:419-25
   Google Scholar
• Zouboulis CC, Seltmann H, Alestas T. Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis. Exp Dermatol 2010;19:148-50
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Nestoris S, Adler YD, A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol 2003;139:668-70
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Saborowski A, Boschnakow A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology 2005;210:36-8
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinol 2009;1:188-92
   PubMedGoogle Scholar
• Nakatsuji T, Liu YT, Huang CP, Antibodies elicited by inactivated propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris. J Invest Dermatol 2008;128:2451-7
   PubMed Web of Science ®Google Scholar
• Wille JJ, Kydonieus A. Palmitoleic acid isomer (C16:1delta6) in human skin sebum is effective against gram-positive bacteria. Skin Pharmacol Appl Skin Physiol 2003;16:176-87
   PubMedGoogle Scholar
• Nakatsuji T, Kao MC, Zhang L, Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression. J Invest Dermatol 2010;130:985-94
   PubMed Web of Science ®Google Scholar
• Nakatsuji T, Kao MC, Fang JY, Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris. J Invest Dermatol 2009;129:2480-8
   PubMed Web of Science ®Google Scholar
• Park J, Lee J, Jung E, In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against propionibacterium sp. Eur J Pharmacol 2004;496:189-95
   PubMed Web of Science ®Google Scholar
• Lee J, Jung E, Park J, Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med 2005;71:338-43
   PubMed Web of Science ®Google Scholar
• Lim YH, Kim IH, Seo JJ. In vitro activity of kaempferol isolated from the Impatiens balsamina alone and in combination with erythromycin or clindamycin against Propionibacterium acnes. J Microbiol 2007;45:473-7
   PubMed Web of Science ®Google Scholar
• Layton AM, Dreno B, Gollnick HPM, A review of the European directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006;20:773-6
   PubMed Web of Science ®Google Scholar
• Nast A, Bayerl C, Borelli C, S2k-Leitlinie zur Therapie der Akne. J Dtsch Dermatol Ges 2010;8:S1-59
   Google Scholar